

DIYABETİK AYAKTA HİPERBARİK OKSİJEN TEDAVİSİ


Akın Savaş Toklu


İ.Ü. İstanbul Tıp Fakültesi, Sualtı Hekimliği ve
Hiperbarik Tıp AD

SUNUM PLANI

- Yara iyileşmesi
- Hiperbarik oksijen tedavis (HBO_2)-geçmişi
- HBO_2 'nin etki mekanizması ve uygulama şekli
- HBO_2 ve Diyabetik Ayak

YARA İYİLEŞMESİNİN AŞAMALARI




The image shows a cross-section of a blood vessel. The vessel lumen is at the top, with a white background. The vessel wall is depicted with a thick red border at the top and bottom. The main part of the vessel wall is a light pinkish-grey color. Scattered throughout this wall are several red blood cells (red circles) and yellow blood cells (yellow circles). Two larger, white, oval-shaped cells with blue nuclei are also present. In the center of the vessel wall, there is a large, red, teardrop-shaped area that contains white text.


Proinflatuar
sitokinler ve büyüme faktörler
(PDGF, VEGF, FGF,
EGF, TGF- β)

YARA İYİLEŞMESİ


- Yara
 - Derinlik
 - Genişlik
 - Tipi
 - Lokalizasyonu
- Enfeksiyon
- Konak özellikleri
(sistemik hastalık, yaş)




İNFLAMASYON




İNFLAMASYON




İNFLAMASYON



PROLİFERASYON



PROLİFERASYON / MATURASYON



YARA İYİLEŞMESİNİN AŞAMALARI

- Fibroblastik proliferasyon
- Kollagen üretimi, salınımı ve köprüleşmesi
- Neovaskülerizasyon
- Epitelizasyon
- Osteogenez

HİPERBARİK OKSİJEN TEDAVİSİ (HBO₂)

- Bir basınç odası içinde tümüyle basınç altına alınan hastaya belirli aralıklarla % 100 oksijen solutarak uygulanan bir tedavi yöntemidir.
- Tedavi basıncı genellikle 2 ATA - 3 ATA arasında ve değişik süre ile uygulanır.

BASINÇ ODALARI



BASINÇ ODALARI



BASINÇ ODALARI





% 100 O₂
≥ 1 ATA

HİPERBARİK OKSİJEN TEDAVISI



- 1 ATA'lık normal atmosfer basıncında %100 oksijen soluma ya da oksijenin topikal kullanımı HBO_2 olarak kabul edilmez.


HİPERBARİK OKSİJEN TEDAVİSİNİN GEÇMİŞİ



- 1650, Otto Von Guericke
- 1662, Henshaw, Domicilium
“...seemed like a good idea”

HİPERBARİK OKSİJEN TEDAVİSİNİN GEÇMİŞİ

- 1879, Fontaine,
Seyyar basınç odası




HİPERBARİK OKSİJEN TEDAVİSİNİN GEÇMİŞİ



- 1921, Cunningham
- 1928 “Çelik küre hastane”




HİPERBARİK OKSİJEN TEDAVİSİNİN GEÇMİŞİ





HİPERBARİK OKSİJEN TEDAVİSİNİN GEÇMİŞİ



HİPERBARİK OKSİJEN TEDAVİSİNİN GEÇMİŞİ



HİPERBARİK OKSİJEN TEDAVİSİNİN GEÇMİŞİ






HİPERBARİK OKSİJEN TEDAVİSİNİN GEÇMİŞİ

- 1937, Dekompresyon hastalığında HBO_2
- 1955, Churchill-Davidson, HBO_2
 - Kanser hastalarında radyoterapinin etkisini arttırmak amacıyla



HİPERBARİK OKSİJEN TEDAVİSİNİN GEÇMİŞİ


- 1960, Boerama, HBO_2 +Kalp cerrahisi
 - Büyük damar transpozisyonu, fallot tetralojisi, pulmoner stenoz

HİPERBARİK OKSİJEN TEDAVİSİNİN GEÇMİŞİ



HİPERBARİK OKSİJEN TEDAVİSİNİN GEÇMİŞİ











HİPERBARİK OKSİJEN TEDAVİSİNİN GEÇMİŞİ



HİPERBARİK OKSİJEN TEDAVİSİNİN GEÇMİŞİ



ORIGINAL PAPERS

Life without blood

(A study of the influence of high atmospheric pressure and hypothermia
on dilution of the blood)

by

I. BOEREMA (*), N. G. MEYNE, W. K. BRUMMELKAMP
S. BOUMA, M. H. MENSCH, F. KAMERMANS, M. STERN HANF
and W. VAN AALDEREN

(from the Surgical Department of the University of Amsterdam)

HİPERBARİK OKSİJEN TEDAVİSİNİN GEÇMİŞİ

Summary

The authors lowered the level of haemoglobin in young pigs to 0.4 per cent, exchanging the blood by plasma or by rheomacrodex. The animals, breathing oxygen at a pressure of 3 atmospheres in a high pressure tank, lived for 45 minutes with a level of haemoglobin not compatible with life when at normal atmospheric pressure.

During all this time the EEG showed no pathological changes, the circulation and blood pressure remained spontaneously normal.

Recovery was uneventful after re-infusion of normal blood.

HİPERBARİK OKSİJEN TEDAVİSİNİN GEÇMİŞİ

- 1962, Simith and Sharp, karbonmonoksit zehirlenmelerinde
- Termal yanıklarda, riskli deri grefti ve flepler, iyileşmeyen problemlili yaralarda HBO_2

Radiation necrosis, decompression sickness, gas embolism, soft tissue infection, soft tissue necrosis, bacteroides infection, compromised skin grafts, fungal infections, mucor mycosis, anemia from blood loss, carbon tetrachloride poisoning, fractures, leprosy, meningitis, radiation myelitis, cystitis and enteritis, retinal artery insufficiency, chronic brain ischemia, senility, multi-infarct dementia, infant cardiac surgery, chronic ulcers, peripheral vascular disease, diabetic neuropathy, acute endocarditis, hearing loss, cortical blindness, cellulitis, infected pacemaker, Hunler's syndrome, post-cardiac arrest, scleroderma, mycobacterium TB, abscesses, asthma, pneumomediastinum, hanging, thrombophlebitis, Lyell's syndrome, CO poisoning, gas gangrene, osteomyelitis, Crohn's DZ, Cyanide poisoning, crush injury with ischemia, Alzheimers...Thermal burns, head and spinal injury, bone grafts, frost bite, CVA's, Hydrogen sulfide poisoning, cancer therapy, Pseudomembraneous colitis, sickle cell crisis, MS, pyoderma gangrenosum, acute MI, carotid aneurysm, aortic aneurysm, anaerobic infections, post-cardiac surgery, pulmonary insufficiency, arteriosclerosis, causalgia, collagen vascular diseases, post-op confusion, traumatic amputation, pulmonary emboli, drowning, moyamoya, surgical empyema, pharyngeal fistula, brain cyst, stenotic valvular heart DZ, tetanus, intestinal obstruction, necrotizing fasciitis, post-epileptic headache, radiation pneumonia, balloon aspiration, migraine, allergic reactions, quadriplegia, dust induced bronchitis, gastroduodenal ulcer, facial neuritis, late pregnancy toxemia, liver

Basıncı odaları sayısında artış



ENDİKASYON DIŞI KULLANIM







ÜLKEMİZDE HIPERBARİK TIP

- 1976 Gölcük ve Çubuklu'da çeşitli çalışmalar
- 1976 İTF-Kurtarma Sualtı Komutanlığı protokolü
- 1981 Deniz Tababeti-Deniz ve Sualtı Hekimliği
- 1984 İTF Bilim Dalı
- 1985 GATA Anabilim Dalı
- 1989 İTF Anabilim Dalı

ÜLKEMİZDE HIPERBARİK TIP

- Dekompresyon hastalığı (vurgun)
- Hava ve gaz embolisi
- Karbonmonoksit, siyanid zehirlenmesi, akut duman inhalasyonu,
- Gazlı gangren
- Yumuşak dokunun nekrotizan enfeksiyonları (derialtı, kas, fas, fasya)
- Crush yaralanmaları, kompartman sendromu ve diğer akut travmatik iskemiler.
- Yara iyileşmesinin geciktiği durumlar (diyabetik ve non-diyabetik)
- Kronik refrakter osteomyelit
- Aşırı kan kaybı
- Radyasyon nekrozları
- Tutması şüpheli deri flepleri ve greftleri
- Termal yanıklar
- Beyin absesi
- Anoksik ensefalopati
- Ani işitme kaybı
- Retinal arter oklüzyonu
- Kafa kemikleri, sternum ve vertebraların akut osteomyelitleri

ÜLKEMİZDE HIPERBARİK TIP


- Dekompresyon hastalığı (vurgun)
- Hava ve gaz embolisi
- Karbonmonoksit, siyanid zehirlenmesi, akut duman inhalasyonu,
- Gazlı gangren
- Yumuşak dokunun nekrotizan enfeksiyonları (derialtı, kas, fas, fasya)
- Crush yaralanmaları, kompartman sendromu ve diğer akut travmatik iskemiler.
- Yara iyileşmesinin geciktiği durumlar (diyabetik ve non-diyabetik)
- Kronik refrakter osteomyelit
- Aşırı kan kaybı
- Radyasyon nekrozları
- Tutması şüpheli deri flepleri ve greftleri
- Termal yanıklar
- Beyin absesi
- Anoksik ensefalopati
- Ani işitme kaybı
- Retinal arter oklüzyonu
- Kafa kemikleri, sternum ve vertebraların akut osteomyelitleri

HBO₂'NİN ETKİ MEKANİZMASI VE UYGULAMA ŞEKLİ




HBO₂'NİN ETKİ MEKANİZMASI VE UYGULAMA ŞEKLİ


- Basıncın direkt etkisi



HBO₂'NİN ETKİ MEKANİZMASI VE UYGULAMA ŞEKLİ

- Basıncın direkt etkisi
- Çözünmüş oksijenin etkisi





P_2




UDAİS


ULUSAL DİYABETİK AYAK
İNFEKSİYONLARI SİMPOZYUMU



DAİÇG

KLİNİK DERNEĞİ
DİYABETİK AYAK İNFEKSİYONLARI ÇALIŞMA GRUBU








<u>TOPLAM BASINÇ</u>		<u>PAO₂ mmHg</u>	<u>PAO₂ mmHg</u>
<u>ATA</u>	<u>mmHg</u>	<u>Hava Solumu</u>	<u>O₂ Solumu</u>
1	760	102	673
2	1520	262	1433
2,5	1900	342	1813
3	2280	422	2193

HBO₂'NİN ETKİ MEKANİZMASI VE UYGULAMA ŞEKLİ


- 1 gr Hb 1,34 ml oksijen taşıyabilir.
- 100 ml kan (Hb 15 gr) 20,1 ml oksijen taşır.
- Kanın O₂ içeriği
$$= (\text{Hb} \times 1,34 \text{ ml} \times \text{SaO}_2) + (0,003 \text{ ml} \times \text{PaO}_2)$$








<u>TOPLAM BASINÇ</u>		<u>PAO₂ mmHg</u>	<u>PAO₂ mmHg</u>
<u>ATA</u>	<u>mmHg</u>	<u>Hava Solumu</u>	<u>O₂ Solumu</u>
1	760	102	673
2	1520	262	1433
2,5	1900	342	1813
3	2280	422	2193 




	Arteriyel pO ₂	TcpO ₂	Yara pO ₂
1 ATA hava (159)	100	70-75	5-20
1 ATA O ₂ (760)	600	450-550	200-400
2,5 ATA (1900)	1800	1400-1500	800-1100



HBO₂'NİN ETKİ MEKANİZMASI VE UYGULAMA ŞEKLİ

- Basıncın direkt etkisi
- Çözünmüş oksijenin etkisi
 - Antihipoksik etki
 - Antiödem etki
 - Antibakteriyel etki
 - Antitoksik
 - Yara iyileşmesi üzerine etki

HBO₂'NİN ETKİ MEKANİZMASI VE UYGULAMA ŞEKLİ



HBO₂'NİN ETKİ MEKANİZMASI VE UYGULAMA ŞEKLİ

- 2-2,5 ATA
- Günde 1-2 seans
- Haftada 5-6 seans
- Toplam 30-60 seans

HANGI DIYABETİK AYAKLARDA HBO₂



UHM 2015, VOL. 42, NO. 3 - CLINICAL PRACTICE GUIDELINE FOR HBO₂ TO TREAT DFU

A clinical practice guideline for the use of hyperbaric oxygen therapy in the treatment of diabetic foot ulcers

CPG Authors: Enoch T. Huang, Jaleh Mansouri, M. Hassan Murad, Warren S. Joseph, Michael B. Strauss, William Tettelbach, Eugene R. Worth

UHMS CPG Oversight Committee: Enoch T. Huang, John Feldmeier, Ken LeDez, Phi-Nga Jeannie Le, Jaleh Mansouri, Richard Moon, M. Hassan Murad

CORRESPONDING AUTHOR: Dr. Enoch T. Huang – enoch.huang@mac.com

HBO₂ VE DIYABETİK AYAK (UHMS)



RECOMMENDATION 1: In patients with Wagner Grade 2 or lower diabetic foot ulcers, we suggest against using hyperbaric oxygen therapy (very low-level evidence in support of HBO₂, conditional recommendation).

HBOT VE DIYABETİK AYAK (UHMS)



RECOMMENDATION 2: In patients with Wagner Grade 3 or higher diabetic foot ulcers that have not shown significant improvement after 30 days of treatment, we suggest adding hyperbaric oxygen therapy to the standard of care to reduce the risk of major amputation and incomplete healing (moderate-level evidence, conditional recommendation).

HBOT VE DIYABETİK AYAK (UHMS)



RECOMMENDATION 3: In patients with Wagner Grade 3 or higher diabetic foot ulcers who have just had a surgical debridement of an infected foot (e.g., partial toe or ray amputation; debridement of ulcer with underlying bursa, cicatrix or bone; foot amputation; incision and drainage [I&D] of deep space abscess; or necrotizing soft tissue infection), we suggest adding acute post-operative hyperbaric oxygen therapy to the standard of care to reduce the risk of major amputation and incomplete healing (moderate-level evidence, conditional recommendation).

HBOT VE DIYABETİK AYAK (ECHM)



Diving and Hyperbaric Medicine Volume 47 No. 1 March 2017

Consensus Conference

Tenth European Consensus Conference on Hyperbaric Medicine:
recommendations for accepted and non-accepted clinical indications
and practice of hyperbaric oxygen treatment

Daniel Mathieu, Alessandro Marroni and Jacek Kot



HBOT VE DIYABETİK AYAK (ECHM)

Table 1

Consensus-based and GRADE scaling for recommendations; GRADE – Grading of Recommendations Assessment, Development and Evaluation System

Strength of recommendation (consensus-based)

Level 1 = Strong recommendation = “*We recommend...*”

The course of action is considered appropriate by the large majority of experts with no major dissension. The panel is confident that the desirable effects of adherence to the recommendation outweigh the undesirable effects.

Level 2 = Weak recommendation = “*We suggest...*”

The course of action is considered appropriate by the majority of experts but some degree of dissension exists amongst the panel. The desirable effects of adherence to the recommendation probably outweigh the undesirable effects.

Level 3 = Neutral recommendation = “*It would be reasonable...*”

The course of action could be considered appropriate in the right context.

No recommendation

No agreement was reached by the group of experts.

Level of evidence (based on GRADE system)

Grade A = High level of evidence

The true effect lies close to our estimate of the effect.

Grade B = Moderate level of evidence

The true effect is likely to be close to our estimate of the effect, but there is a possibility that it is substantially different.

Grade C = Low level of evidence

The true effect may be substantially different from our estimate of the effect.

Grade D = Very low level of evidence

Our estimate of the effect is just a guess, and it is very likely that the true effect is substantially different from our estimate of the effect.

HBOT VE DIYABETİK AYAK (ECHM)

Table 2

Recommendations on the indications accepted for HBOT (there was no Level A evidence)

Condition	Level of evidence		Agreement level
	B	C	
Type 1			
CO poisoning	X		Strong agreement
Open fractures with crush injury	X		Strong agreement
Prevention of osteoradionecrosis after dental extraction	X		Strong agreement
Osteoradionecrosis (mandible)	X		Strong agreement
Soft tissue radionecrosis (cystitis, proctitis)	X		Strong agreement
Decompression illness		X	Strong agreement
Gas embolism		X	Strong agreement
Anaerobic or mixed bacterial infections		X	Strong agreement
Sudden deafness	X		Strong agreement
Type 2			
Diabetic foot lesions	X		Strong agreement
Femoral head necrosis	X		Strong agreement
Compromised skin grafts and musculo-cutaneous flaps		X	Strong agreement
Central retinal artery occlusion (CRAO)		X	Strong agreement
Crush Injury without fracture		X	Agreement
Osteoradionecrosis (bones other than mandible)		X	Agreement
Radio-induced lesions of soft tissues (other than cystitis and proctitis)		X	Agreement

HBOT VE DIYABETİK AYAK (ECHM)

- In the diabetic patient, the use of HBOT is recommended in the presence of a chronic critical ischaemia as defined by the European Consensus Conference on Critical Ischemia (see note below), if TCOM readings under hyperbaric conditions (253 kPa, 100% oxygen) are higher than 100 mmHg (Type 1 recommendation, level A evidence).
- Note: Chronic critical ischaemia can be recognised when there is: periodic pain, persistent at rest, needing regular analgesic treatment for more than two weeks, or ulceration or gangrene of foot or toes with ankle systolic pressure < 30 mmHg in the diabetic.¹¹
- However, despite the strong agreement on the validity of the criteria listed above to properly select patients for HBOT, the jury acknowledges the fact not all hyperbaric centres are able to perform TCOM under hyperbaric conditions (253 kPa, 100% oxygen). Therefore, owing to this limitation, we suggest HBOT in diabetic foot ulcers (grade 3 and above of Wagner classification, stage B, grade 3 and above of University of Texas classification) that have failed to respond to adequate basic wound care after four weeks (Type 2 recommendation, Level B evidence).

HBOT VE DIYABETİK AYAK (ECHM)

- Kritik iskemi
 - İstirahatte geçmeyen, iki haftadan daha uzun süre analjezik tedavi gerektiren periyodik ağrı, ayakta ülser veya gangren, ayak bileği sistolik basıncı < 30 mmHg
- 2,5 ATA da $TcPO_2 > 100$ mmHg
- 4 Haftadır standart tedaviye cevap alınamamış Wagner 3 ve üzeri

HBO₂ ve DA-Randomize Kontrollü Çalışmalar

1. Abidia, A., et al., *The role of hyperbaric oxygen therapy in ischaemic diabetic lower extremity ulcers: a double-blind randomised-controlled trial*. Eur J Vasc Endovasc Surg, 2003. **25**(6): p. 513-8.
2. Doctor, N., S. Pandya, and A. Supe, Hyperbaric oxygen therapy in diabetic foot. J Postgrad Med, 1992. 38(3): p. 112-4, 111.
3. Duzgun, A.P., et al., Effect of hyperbaric oxygen therapy on healing of diabetic foot ulcers. J Foot Ankle Surg, 2008. 47(6): p. 515-9.
4. Faglia, E., et al., Adjunctive systemic hyperbaric oxygen therapy in treatment of severe prevalently ischemic diabetic foot ulcer. A randomized study. Diabetes Care, 1996. 19(12): p. 1338-43.
5. Fedorko, L., et al., Hyperbaric Oxygen Therapy Does Not Reduce Indications for Amputation in Patients With Diabetes With Nonhealing Ulcers of the Lower Limb: A Prospective, Double-Blind, Randomized Controlled Clinical Trial. Diabetes Care, 2016.
6. Kaur, S., et al., Evaluation of the efficacy of hyperbaric oxygen therapy in the management of chronic nonhealing ulcer and role of periwound transcutaneous oximetry as a predictor of wound healing response: A randomized prospective controlled trial. J Anaesthesiol Clin Pharmacol, 2012. 28(1): p. 70-5.
7. Kessler, L., et al., Hyperbaric oxygenation accelerates the healing rate of nonischemic chronic diabetic foot ulcers: a prospective randomized study. Diabetes Care, 2003. 26(8): p. 2378-82.
8. Londahl, M., et al., Hyperbaric oxygen therapy facilitates healing of chronic foot ulcers in patients with diabetes. Diabetes Care, 2010. 33(5): p. 998-1003.
9. Ma, L., et al., A prospective, randomized, controlled study of hyperbaric oxygen therapy: effects on healing and oxidative stress of ulcer tissue in patients with a diabetic foot ulcer. Ostomy Wound Manage, 2013. 59(3): p. 18-24.

HBO₂ ve DA-Randomize Kontrollü Çalışmalar

1. Abidia, A., et al., *The role of hyperbaric oxygen therapy in ischaemic diabetic lower extremity ulcers: a double-blind randomised-controlled trial*. Eur J Vasc Endovasc Surg, 2003. **25**(6): p. 513-8.
2. Doctor, N., S. Pandya, and A. Supe, Hyperbaric oxygen therapy in diabetic foot. J Postgrad Med, 1992. 38(3): p. 112-4, 111.
3. Duzgun, A.P., et al., *Effect of hyperbaric oxygen therapy on healing of diabetic foot ulcers*. J Foot Ankle Surg, 2008. 47(6): p. 515-9.
4. Faglia, E., et al., Adjunctive systemic hyperbaric oxygen therapy in treatment of severe prevalently ischemic diabetic foot ulcer. A randomized study. Diabetes Care, 1996. 19(12): p. 1338-43.
5. Fedorko, L., et al., Hyperbaric Oxygen Therapy Does Not Reduce Indications for Amputation in Patients With Diabetes With Nonhealing Ulcers of the Lower Limb: A Prospective, Double-Blind, Randomized Controlled Clinical Trial. Diabetes Care, 2016.
6. Kaur, S., et al., Evaluation of the efficacy of hyperbaric oxygen therapy in the management of chronic nonhealing ulcer and role of periwound transcutaneous oximetry as a predictor of wound healing response: A randomized prospective controlled trial. J Anaesthesiol Clin Pharmacol, 2012. 28(1): p. 70-5.
7. Kessler, L., et al., Hyperbaric oxygenation accelerates the healing rate of nonischemic chronic diabetic foot ulcers: a prospective randomized study. Diabetes Care, 2003. 26(8): p. 2378-82.
8. Londahl, M., et al., Hyperbaric oxygen therapy facilitates healing of chronic foot ulcers in patients with diabetes. Diabetes Care, 2010. 33(5): p. 998-1003.
9. Ma, L., et al., A prospective, randomized, controlled study of hyperbaric oxygen therapy: effects on healing and oxidative stress of ulcer tissue in patients with a diabetic foot ulcer. Ostomy Wound Manage, 2013. 59(3): p. 18-24.

HBO₂ ve DA-Randomize Kontrollü Çalışmalar

Duzgun, A.P., et al., Effect of hyperbaric oxygen therapy on healing of diabetic foot ulcers. J Foot Ankle Surg, 2008. 47(6): p. 515-9.

Effect of Hyperbaric Oxygen Therapy on Healing of Diabetic Foot Ulcers

Arife Polat Duzgun, MD,¹ Hakan Ziya Satır, MD,² Omer Ozozan, MD,¹ Baris Saylam, MD,¹ Bahadır Kulah, MD, MS, FACS,³ and Faruk Coskun, MD⁴

Hyperbaric oxygen therapy can be used as an adjunct to standard wound care in the treatment of diabetic patients with foot ulcers. We undertook a prospective, randomized investigation of the use of hyperbaric oxygen therapy versus standard therapy for the treatment of foot ulcers in diabetic patients. A number of demographic variables were analyzed in regard to wound healing. We noted that foot ulcers in patients in the hyperbaric oxygen therapy group were more likely to heal, and were more likely to undergo amputation distal to the metatarsophalangeal joint compared with those patients receiving standard therapy without hyperbaric oxygen. We feel that hyperbaric oxygen therapy should be considered a useful adjunct in the management of foot ulcers in diabetic patients. Level of Clinical Evidence: 2 (The Journal of Foot & Ankle Surgery 47(6):515-519, 2008)

determine appropriate antibiotic therapy. In the HBOT group, standard therapy was supplemented by hyperbaric oxygen treatments administered at a maximum working pressure of 20 atmospheres absolute (ATA), using a unichamber pressure room (Patterson Companies, Inc., St. Paul, MN) employing a volume of 10 m³ at 2 to 3 ATA for 90 minutes. Treatment was administered as 2 sessions per day, followed by 1 session on the following day, alternating throughout the course of therapy, which typically extended for a period of 20 to 30 days.

HBO₂ ve DA-Randomize Kontrollü Çalışmalar

1. Abidia, A., et al., *The role of hyperbaric oxygen therapy in ischaemic diabetic lower extremity ulcers: a double-blind randomised-controlled trial*. Eur J Vasc Endovasc Surg, 2003. **25**(6): p. 513-8.
2. Doctor, N., S. Pandya, and A. Supe, Hyperbaric oxygen therapy in diabetic foot. J Postgrad Med, 1992. 38(3): p. 112-4, 111.
3. Duzgun, A.P., et al., Effect of hyperbaric oxygen therapy on healing of diabetic foot ulcers. J Foot Ankle Surg, 2008. 47(6): p. 515-9.
4. Faglia, E., et al., Adjunctive systemic hyperbaric oxygen therapy in treatment of severe prevalently ischemic diabetic foot ulcer. A randomized study. Diabetes Care, 1996. 19(12): p. 1338-43.
5. Fedorko, L., et al., Hyperbaric Oxygen Therapy Does Not Reduce Indications for Amputation in Patients With Diabetes With Nonhealing Ulcers of the Lower Limb: A Prospective, Double-Blind, Randomized Controlled Clinical Trial. Diabetes Care, 2016.
6. Kaur, S., et al., Evaluation of the efficacy of hyperbaric oxygen therapy in the management of chronic nonhealing ulcer and role of periwound transcutaneous oximetry as a predictor of wound healing response: A randomized prospective controlled trial. J Anaesthesiol Clin Pharmacol, 2012. 28(1): p. 70-5.
7. Kessler, L., et al., Hyperbaric oxygenation accelerates the healing rate of nonischemic chronic diabetic foot ulcers: a prospective randomized study. Diabetes Care, 2003. 26(8): p. 2378-82.
8. Londahl, M., et al., Hyperbaric oxygen therapy facilitates healing of chronic foot ulcers in patients with diabetes. Diabetes Care, 2010. 33(5): p. 998-1003.
9. Ma, L., et al., A prospective, randomized, controlled study of hyperbaric oxygen therapy: effects on healing and oxidative stress of ulcer tissue in patients with a diabetic foot ulcer. Ostomy Wound Manage, 2013. 59(3): p. 18-24.

HBO₂ ve DA-Randomize kontrollü çalışmalar

1. Abidia, A., et al., *The role of hyperbaric oxygen therapy in ischaemic diabetic lower extremity ulcers: a double-blind randomised-controlled trial.* Eur J Vasc Endovasc Surg, 2003. **25**(6): p. 513-8.
2. Doctor, N., S. Pandya, and A. Supe, Hyperbaric oxygen therapy in diabetic foot. J Postgrad Med, 1992. 38(3): p. 112-4, 111.
3. Duzgun, A.P., et al., Effect of hyperbaric oxygen therapy on healing of diabetic foot ulcers. J Foot Ankle Surg, 2008. 47(6): p. 515-9.
4. Faglia, E., et al., Adjunctive systemic hyperbaric oxygen therapy in treatment of severe prevalently ischemic diabetic foot ulcer. A randomized study. Diabetes Care, 1996. 19(12): p. 1338-43.
5. Fedorko, L., et al., **Hyperbaric Oxygen Therapy Does Not Reduce Indications for Amputation in Patients With Diabetes With Nonhealing Ulcers of the Lower Limb: A Prospective, Double-Blind, Randomized Controlled Clinical Trial.** Diabetes Care, 2016.
6. Kaur, S., et al., Evaluation of the efficacy of hyperbaric oxygen therapy in the management of chronic nonhealing ulcer and role of periwound transcutaneous oximetry as a predictor of wound healing response: A randomized prospective controlled trial. J Anaesthesiol Clin Pharmacol, 2012. 28(1): p. 70-5.
7. Kessler, L., et al., Hyperbaric oxygenation accelerates the healing rate of nonischemic chronic diabetic foot ulcers: a prospective randomized study. Diabetes Care, 2003. 26(8): p. 2378-82.
8. Londahl, M., et al., Hyperbaric oxygen therapy facilitates healing of chronic foot ulcers in patients with diabetes. Diabetes Care, 2010. 33(5): p. 998-1003.
9. Ma, L., et al., A prospective, randomized, controlled study of hyperbaric oxygen therapy: effects on healing and oxidative stress of ulcer tissue in patients with a diabetic foot ulcer. Ostomy Wound Manage, 2013. 59(3): p. 18-24.



CrossMark

Hyperbaric Oxygen Therapy Does Not Reduce Indications for Amputation in Patients With Diabetes With Nonhealing Ulcers of the Lower Limb: A Prospective, Double-Blind, Randomized Controlled Clinical Trial

Ludwik Fedorko,¹ James M. Bowen,^{2,3} Wilhelmine Jones,¹ George Oreopoulos,¹ Ron Goeree,^{2,3} Robert B. Hopkins,^{2,3} and Daria J. O'Reilly^{2,3}



HBO₂ ve DA-Gözlemsel çalışmalar

1. Baroni, G., et al., Hyperbaric oxygen in diabetic gangrene treatment. Diabetes Care, 1987. 10(1): p. 81-6.
2. Cianci, P., Adjunctive hyperbaric oxygen therapy in the treatment of the diabetic foot. J Am Podiatr Med Assoc, 1994.
3. 84(9): p. 448-55.
4. Davis, J.C., The use of adjuvant hyperbaric oxygen in treatment of the diabetic foot. Clin Podiatr Med Surg, 1987.
5. 4(2): p. 429-37.
6. Eggert, J.V., E.R. Worth, and C.C. Van Gils, Cost and mortality data of a regional limb salvage and hyperbaric medicine program for Wagner Grade 3 or 4 diabetic foot ulcers. Undersea Hyperb Med, 2016. 43(1): p. 1-8.
7. Faglia, E., et al., Predictive values of transcutaneous oxygen tension for above-the-ankle amputation in diabetic patients with critical limb ischemia. Eur J Vasc Endovasc Surg, 2007. 33(6): p. 731-6.
8. Faglia, E., et al., Change in major amputation rate in a center dedicated to diabetic foot care during the 1980s: prognostic determinants for major amputation. J Diabetes Complications, 1998. 12(2): p. 96-102.
9. Fife, C.E., et al., Factors influencing the outcome of lower-extremity diabetic ulcers treated with hyperbaric oxygen therapy. Wound Repair Regen, 2007. 15(3): p. 322-31.
10. Fife, C.E., et al., The predictive value of transcutaneous oxygen tension measurement in diabetic lower extremity ulcers treated with hyperbaric oxygen therapy: a retrospective analysis of 1,144 patients. Wound Repair Regen, 2002. 10(4): p. 198-207.
11. Kalani, M., et al., Hyperbaric oxygen (HBO) therapy in treatment of diabetic foot ulcers. Long-term follow-up. J Diabetes Complications, 2002. 16(2): p. 153-8.
12. Kaya, A., et al., Can major amputation rates be decreased in diabetic foot ulcers with hyperbaric oxygen therapy? Int Orthop, 2009. 33(2): p. 441-6.
13. Oriani, G., et al., Hyperbaric Oxygen Therapy in Diabetic Gangrene. Journal of Hyperbaric Medicine, 1990. 5(3): p. 171-175.
14. Oriani, G., et al., Diabetic Foot and Hyperbaric Oxygen Therapy: A Ten-Year Experience. Journal of Hyperbaric Medicine, 1992. 7(4): p. 213-221.
15. Zamboni, W.A., et al., Evaluation of hyperbaric oxygen for diabetic wounds: a prospective study. Undersea Hyperb Med, 1997. 24(3): p. 175-9.

HBO₂ ve DA-Meta analiz / sistematik değerlendirme

1. Bishop, A.J. and E. Mudge, *Diabetic foot ulcers treated with hyperbaric oxygen therapy: a review of the literature*. Int Wound J, 2014. **11**(1): p. 28-34.
2. Game, F.L., et al., *A systematic review of interventions to enhance the healing of chronic ulcers of the foot in diabetes*. Diabetes Metab Res Rev, 2012. **28 Suppl 1**: p. 119-41.
3. Goldman, R.J., *Hyperbaric oxygen therapy for wound healing and limb salvage: a systematic review*. PM R, 2009. **1**(5): p. 471-89.
4. Huang, E.T., et al., *A clinical practice guideline for the use of hyperbaric oxygen therapy in the treatment of diabetic foot ulcers*. Undersea Hyperb Med, 2015. **42**(3): p. 205-47.
5. Kranke, P., et al., *Hyperbaric oxygen therapy for chronic wounds*. Cochrane Database Syst Rev, 2012. **4**: p. CD004123.
6. Liu, R., et al., *Systematic review of the effectiveness of hyperbaric oxygenation therapy in the management of chronic diabetic foot ulcers*. Mayo Clin Proc, 2013. **88**(2): p. 166-75.
7. Londahl, M., *Hyperbaric oxygen therapy as adjunctive treatment for diabetic foot ulcers*. Int J Low Extrem Wounds, 2013. **12**(2): p. 152-7.
8. Margolis, D.J., et al., *Lack of effectiveness of hyperbaric oxygen therapy for the treatment of diabetic foot ulcer and the prevention of amputation: a cohort study*. Diabetes Care, 2013. **36**(7): p. 1961-6.
9. Murad, M.H., et al., *Using GRADE for evaluating the quality of evidence in hyperbaric oxygen therapy clarifies evidence limitations*. J Clin Epidemiol, 2014. **67**(1): p. 65-72.
10. O'Reilly, D., et al., *Hyperbaric Oxygen Therapy for Diabetic Ulcers: Systematic Review and Meta-Analysis*. International Journal of Technology Assessment in Health Care, 2013. **29**(3): p. 269-281.
11. Roeckl-Wiedmann, I., M. Bennett, and P. Kranke, *Systematic review of hyperbaric oxygen in the management of chronic wounds*. Br J Surg, 2005. **92**(1): p. 24-32.
12. Stoekenbroek, R.M., et al., *Hyperbaric oxygen for the treatment of diabetic foot ulcers: a systematic review*. Eur J Vasc Endovasc Surg, 2014. **47**(6): p. 647-55.
13. Wang, Z., et al., *A systematic review and meta-analysis of tests to predict wound healing in diabetic foot*. J Vasc Surg, 2016. **63**(2 Suppl): p. 29S-36S e1-2.
14. Wunderlich, R.P., E.J. Peters, and L.A. Lavery, *Systemic hyperbaric oxygen therapy: lower-extremity wound healing and the diabetic foot*. Diabetes Care, 2000. **23**(10): p. 1551-5.

HBO₂ ve DA-Meta analiz / sistematik değerlendirme

1. Bishop, A.J. and E. Mudge, *Diabetic foot ulcers treated with hyperbaric oxygen therapy: a review of the literature*. Int Wound J, 2014. **11**(1): p. 28-34.
2. Game, F.L., et al., *A systematic review of interventions to enhance the healing of chronic ulcers of the foot in diabetes*. Diabetes Metab Res Rev, 2012. **28 Suppl 1**: p. 119-41.
3. Goldman, R.J., *Hyperbaric oxygen therapy for wound healing and limb salvage: a systematic review*. PM R, 2009. **1**(5): p. 471-89.
4. Huang, E.T., et al., *A clinical practice guideline for the use of hyperbaric oxygen therapy in the treatment of diabetic foot ulcers*. Undersea Hyperb Med, 2015. **42**(3): p. 205-47.
5. Kranke, P., et al., *Hyperbaric oxygen therapy for chronic wounds*. Cochrane Database Syst Rev, 2012. **4**: p. CD004123.
6. Liu, R., et al., *Systematic review of the effectiveness of hyperbaric oxygenation therapy in the management of chronic diabetic foot ulcers*. Mayo Clin Proc, 2013. **88**(2): p. 166-75.
7. Londahl, M., *Hyperbaric oxygen therapy as adjunctive treatment for diabetic foot ulcers*. Int J Low Extrem Wounds, 2013. **12**(2): p. 152-7.
8. Margolis, D.J., et al., *Lack of effectiveness of hyperbaric oxygen therapy for the treatment of diabetic foot ulcer and the prevention of amputation: a cohort study*. Diabetes Care, 2013. **36**(7): p. 1961-6.
9. Murad, M.H., et al., *Using GRADE for evaluating the quality of evidence in hyperbaric oxygen therapy clarifies evidence limitations*. J Clin Epidemiol, 2014. **67**(1): p. 65-72.
10. O'Reilly, D., et al., *Hyperbaric Oxygen Therapy for Diabetic Ulcers: Systematic Review and Meta-Analysis*. International Journal of Technology Assessment in Health Care, 2013. **29**(3): p. 269-281.
11. Roeckl-Wiedmann, I., M. Bennett, and P. Kranke, *Systematic review of hyperbaric oxygen in the management of chronic wounds*. Br J Surg, 2005. **92**(1): p. 24-32.
12. Stoekenbroek, R.M., et al., *Hyperbaric oxygen for the treatment of diabetic foot ulcers: a systematic review*. Eur J Vasc Endovasc Surg, 2014. **47**(6): p. 647-55.
13. Wang, Z., et al., *A systematic review and meta-analysis of tests to predict wound healing in diabetic foot*. J Vasc Surg, 2016. **63**(2 Suppl): p. 29S-36S e1-2.
14. Wunderlich, R.P., E.J. Peters, and L.A. Lavery, *Systemic hyperbaric oxygen therapy: lower-extremity wound healing and the diabetic foot*. Diabetes Care, 2000. **23**(10): p. 1551-5.

HBO₂ ve DA-Meta analiz / sistematik değerlendirme

Margolis, D.J., et al., Lack of effectiveness of hyperbaric oxygen therapy for the treatment of diabetic foot ulcer and the prevention of amputation: a cohort study. Diabetes Care, 2013. 36(7): p. 1961-6.

Lack of Effectiveness of Hyperbaric Oxygen Therapy for the Treatment of Diabetic Foot Ulcer and the Prevention of Amputation

A cohort study

DAVID J. MARGOLIS, MD, PHD^{1,2}
JAYANTA GUPTA, MD, PHD²
OLE HOFFSTAD, MS²
MARYTE PAPDOPOULOS, BA²

HENRY A. GLICK, PHD³
STEPHEN R. THOM, MD, PHD⁴
NANDITA MITRA, PHD²

OBJECTIVE—Hyperbaric oxygen (HBO) is a device that is used to treat foot ulcers. The study goal was to compare the effectiveness of HBO with other conventional therapies administered in a wound care network for the treatment of a diabetic foot ulcer and prevention of lower-extremity amputation.

RESEARCH DESIGN AND METHODS—This was a longitudinal observational cohort study. To address treatment selection bias, we used propensity scores to determine the “propensity” that an individual was selected to receive HBO.

RESULTS—We studied 6,259 individuals with diabetes, adequate lower limb arterial perfusion, and foot ulcer extending through the dermis, representing 767,060 person-days of wound care. In the propensity score-adjusted models, individuals receiving HBO were less likely to have healing of their foot ulcer (hazard ratio 0.68 [95% CI 0.63–0.73]) and more likely to have an amputation (2.37 [1.84–3.04]). Additional analyses, including the use of an instrumental variable, were conducted to assess the robustness of our results to unmeasured confounding. HBO was not found to improve the likelihood that a wound might heal or to decrease the likelihood of amputation in any of these analyses.

CONCLUSIONS—Use of HBO neither improved the likelihood that a wound would heal nor prevented amputation in a cohort of patients defined by Centers for Medicare and Medicaid Services eligibility criteria. The usefulness of HBO in the treatment of diabetic foot ulcers needs to be reevaluated.

Diabetes Care 36:1961–1966, 2013

Hyperbaric oxygen (HBO) therapy is used to treat foot ulcers that have not responded to initial care and thereby to prevent lower-extremity amputations (LEAs), both of which are complications of diabetes. HBO requires the exposure of a patient to 100% oxygen at a pressure two to three times greater than

ambient atmospheric pressure (1). The efficacy of HBO as a treatment for lower-extremity ulcerations has been supported by several small randomized trials; its use also has been advocated by a number of review articles (2–7). However, a meta-analysis of these randomized trials did not find a long-term statistically

significant improvement associated with HBO therapy and concluded that the overall quality of the reviewed studies was poor (8).

Randomized controlled studies are efficacy studies in that they estimate the likelihood that a drug or device, like HBO, will work in an ideal setting. Effectiveness studies estimate the likelihood that a drug or device will work in the “real world.” Effectiveness studies can be difficult to conduct in that the design constraints of a randomized trial create a nonreal-world setting; therefore, frequently, effectiveness is assessed using cohort studies. The propensity score (PS) technique was first described ~30 years ago (9). The goal of this technique is to statistically control variables that might influence the selection of a therapy and thus to mimic the “even” distribution of variables seen in a randomized controlled study.

We compared the effectiveness of HBO with other therapies administered without HBO in a wound care network. We used PS approaches to compensate for the lack of randomized treatment assignment as well as an instrumental variable analysis (Supplementary Data) to confirm our findings.

RESEARCH DESIGN AND METHODS

Longitudinal observational data from the National Healing Corporation (NHC) were used. The study was reviewed and approved by the Institutional Review Board of the University of Pennsylvania. Our presentation is consistent with the STROBE statement for cohort studies.

Population

NHC is a company that provided comprehensive wound care management solutions to local wound care centers across the United States. NHC developed clinical pathways to guide treatment based on reviews of best practice and guidelines on

From the ¹Department of Dermatology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; the ²Department of Biostatistics and Epidemiology, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; the ³Department of Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania; and the ⁴Department of Emergency Medicine, Perelman School of Medicine, University of Pennsylvania, Philadelphia, Pennsylvania.

Corresponding author: David J. Margolis, margo@mail.med.upenn.edu.

Received 22 October 2012 and accepted 9 January 2013.

DOI: 10.2337/dci.12-2160

This article contains Supplementary Data online at <http://care.diabetesjournals.org/lookup/suppl/doi:10.2337/dci.12-2160/-DC1>.

© 2013 by the American Diabetes Association. Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work is not altered. See <http://creativecommons.org/licenses/by-nc-nd/3.0/> for details.

HBO₂ ve DA-Diger yayınlar

- Carter, M.J., C.E. Fife, and M. Bennett, **Comment on: Margolis et al.** lack of Effectiveness of hyperbaric oxygen therapy for the treatment of diabetic foot ulcer and the prevention of amputation: a cohort study. *Diabetes Care* 2013;36:1961-1966. *Diabetes Care*, 2013. **36**(8): p. e131.
- Fedorko, L., et al., Response to Comments on Fedorko et al. Hyperbaric Oxygen Therapy Does Not Reduce Indications for Amputation in Patients With Diabetes With Nonhealing Ulcers of the Lower Limb: A Prospective, Double-Blind, Randomized Controlled Clinical Trial. *Diabetes Care* 2016;39:392-399. *Diabetes Care*, 2016. **39**(8): p. e136-7.
- Gottrup, F., et al., Use of Oxygen Therapies in Wound Healing. *J Wound Care*, 2017. **26**(Sup5): p. S1-S43.
- Huang, E.T., **Comment on Fedorko et al.** Hyperbaric Oxygen Therapy Does Not Reduce Indications for Amputation in Patients With Diabetes With Nonhealing Ulcers of the Lower Limb: A Prospective, Double-Blind, Randomized Controlled Clinical Trial. *Diabetes Care* 2016;39:392-399. *Diabetes Care*, 2016. **39**(8): p. e133-4.
- LeDez, K., Serious concerns about the Toronto Hyperbaric Oxygen for Diabetic Foot Ulcer study. *Undersea Hyperb Med*, 2016. **43**(6): p. 737-741.
- Londahl, M. and P. Katzman, **Comments on Margolis et al.** Lack of effectiveness of hyperbaric oxygen therapy for the treatment of diabetic foot ulcer and the prevention of amputation. *Int Wound J*, 2015. **12**(2): p. 232.
- Londahl, M., K. Fagher, and P. Katzman, **Comment on Fedorko et al.** Hyperbaric Oxygen Therapy Does Not Reduce Indications for Amputation in Patients With Diabetes With Nonhealing Ulcers of the Lower Limb: A Prospective, Double-Blind, Randomized Controlled Clinical Trial. *Diabetes Care* 2016;39:392-399. *Diabetes Care*, 2016. **39**(8): p. e131-2.
- Margolis, D.J., et al., Response to Comments on: Margolis et al. Lack of effectiveness of hyperbaric oxygen therapy for the treatment of diabetic foot ulcer and the prevention of amputation: a cohort study. *Diabetes Care* 2013;36:1961- 1966. *Diabetes Care*, 2013. **36**(8): p. e132-3.
- Mathieu, D., A. Marroni, and J. Kot, Tenth European Consensus Conference on Hyperbaric Medicine: recommendations for accepted and non-accepted clinical indications and practice of hyperbaric oxygen treatment. *Diving Hyperb Med*, 2017. **47**(1): p. 24-32.
- Murad, M.H., **Comment on Fedorko et al.** Hyperbaric Oxygen Therapy Does Not Reduce Indications for Amputation in Patients With Diabetes With Nonhealing Ulcers of the Lower Limb: A Prospective, Double-Blind, Randomized Controlled Clinical Trial. *Diabetes Care* 2016;39:392-399. *Diabetes Care*, 2016. **39**(8): p. e135.

The American Diabetes Association's annual Standards of Medical Care in Diabetes provides comprehensive guidelines for clinicians caring for people with diabetes. The Standards are developed by the Professional Practice Committee (PPC), a multi-disciplinary team of 12 leading experts in the field of diabetes care. On an annual basis, the PPC conducts a comprehensive review of all areas of diabetes care, including foot and wound care. The PPC reviewed the available data on the use of hyperbaric oxygen therapy in 2016 and did not identify enough supporting data on the efficacy of this treatment to recommend its use. The PPC continues to review all treatment options available for people with diabetes with evidence-based criteria for potential inclusion the Association's Standards of Medical Care, a resource for providers and people with diabetes to guide diagnosis and treatment.

William T. Cefalu, MD, Chief Scientific, Medical & Mission Officer of the American Diabetes Association

July 19, 2017

American Diabetes Association
Board of Directors
c/o Michelle Kirkwood
2451 Crystal Drive, Suite 900
Arlington, VA 22202



UHMS
631 US Highway 1, Suite 307
North Palm Beach, FL
Phone: 919-490-5140
Fax: 919-490-5149
www.uhms.org

An open letter to the American Diabetes Association board of directors

Davida A. DeMarco, PhD
Brenda Montgomery, RN,
MSHS, CDE
Alvin C. Powers, MD
Umesh Verma
Felicia Hill-Briggs, PhD, ABPP

Jane Reusch, MD
Michael Ching, CPA
Janet Brown Friday, RN, MSN,
MPH
Robert H. Eckel, MD
David Herrick, MBA

C. Ronald Kahn, MD
Steve Lucas, BS
Calvin Schmidt, BE, MBA
Catherine Squires, CFRE
Alan L. Yatvin, JD

In conclusion, we request a meeting with Dr. Cefalu and the PPC to discuss our concerns about the ADA's interpretation of the literature, petition the ADA board of directors and the PPC to consider amending or revising the ADA position statement, demand a list of scientific references and/or analyses that has led the PPC to their current negative position on the use of adjunctive HBO₂ therapy for the treatment of select DFUs, and ask for a public comment period before making the ADA position final. Anything short of this demonstrates a lack of both transparency and scientific discourse.

Sincerely,




Enoch Huang, MD
President, Undersea and Hyperbaric Medical Society




Jayesh Shah, MD
President, American College of Hyperbaric Medicine




Daniel Mathieu, MD
President, European Committee on Hyperbaric Medicine




Pasquale Longobardi, MD
President, Societa Italiana di Medicina Subacquea ed Iperbarica



Fabrício Valandro Rech, MD
President, Sociedade Brasileira de Medicina Hiperbárica



Debbie Pestell, MD
President, Canadian Undersea and Hyperbaric Medical Association



Jacek Kot, MD
President, European Undersea and Baromedical Society



David Smart, MD
President, South Pacific Underwater Medical Society



Tarun Sahni, MD
President, Hyperbaric Society of India



Magnus Löndahl, MD
President, Swedish Wound Healing Society



Gregory Weir, MD
President, Southern African Underwater and Hyperbaric Medical Association

























































LKI Arşiv



Ben Giderim
Sine Sine

Burhan Çağan

1981

CANLI

